Related Experiment Video

Updated: Oct 17, 2025

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.7K

B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy

Manzar Alam1, Sabeeha Ali1, Taj Mohammad1

  • 1Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India.

International Journal of Molecular Sciences
|October 13, 2021
PubMed

Insights

Defects in apoptosis, regulated by B cell lymphoma 2 (Bcl-2), drive cancer growth. Targeting Bcl-2 with BH3-mimetics offers a promising therapeutic strategy for various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Apoptosis defects promote cancer cell proliferation and survival.
  • B cell lymphoma 2 (Bcl-2) is a key anti-apoptotic protein, central to cancer development.
  • Overexpression of Bcl-2 is common in numerous cancers, making it a significant therapeutic target.

Purpose of the Study:

  • To review the critical role of Bcl-2 in cancer progression and development.
  • To highlight Bcl-2 as a potential therapeutic target for novel anti-cancer strategies.
  • To discuss the therapeutic potential of Bcl-2 inhibitors in cancer management.

Main Methods:

  • Literature review of Bcl-2's function in apoptosis and cancer.
  • Analysis of therapeutic strategies targeting Bcl-2, including BH3-mimetics.
  • Examination of clinical trial data and pre-clinical research on Bcl-2 inhibitors.

Main Results:

  • Bcl-2 overexpression is a hallmark of many cancers, contributing to tumor growth.
  • BH3-mimetics represent a novel class of compounds with demonstrated efficacy in various cancer settings.
  • Bcl-2 inhibitors are under active investigation in clinical trials for multiple cancer types.

Conclusions:

  • Bcl-2's fundamental role in apoptosis regulation makes it a potent target for anti-cancer drug development.
  • Targeting Bcl-2 offers a promising avenue for novel therapeutic strategies against diverse cancers.
  • Bcl-2 inhibitors show significant therapeutic activity and are crucial for advancing cancer treatment.
Keywords:
B cell lymphoma 2apoptosiscancersclinical trialsinhibitorstargeted therapy

More Related Videos

Murine Model of CD40-activation of B cells12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

12.9K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
741
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
10.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K